Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

J-P Lacour1

  • 1Service de dermatologie, hôpital Archet 2, CHU de Nice, CS23079, 06202, Nice, Cedex 3, France.

Annales De Dermatologie Et De Venereologie
|January 31, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Leg ulcers in childhood: A multicenter study in France.

Annales de dermatologie et de venereologie·2021
Same author

Successful treatment of recalcitrant genital lichen planus with secukinumab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Annales de dermatologie et de venereologie·2020
Same author

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

The British journal of dermatology·2020
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Topical steroids and emollients are standard for atopic dermatitis (AD). New biologic therapies and JAK inhibitors are transforming AD treatment, offering alternatives for resistant cases.

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition.
  • Current treatments include topical steroids and emollients.
  • Systemic therapies like cyclosporine and methotrexate are used for resistant AD.

Purpose of the Study:

  • To review the current and emerging therapeutic landscape for atopic dermatitis.
  • To highlight the impact of new biologic therapies and JAK inhibitors on AD management.

Main Methods:

  • Literature review of atopic dermatitis treatments.
  • Analysis of current and pipeline biologic and small molecule therapies.

Main Results:

  • Dupilumab, an anti-IL4/IL13 biologic, is approved for AD treatment.
Keywords:
Atopic dermatitisAtopic eczemaDermatite atopiqueEczéma atopiqueSystemic treatmentTraitement systémique

Related Experiment Videos

  • Other biologics targeting IL-13 and IL-31 are under development.
  • Janus kinase (JAK) inhibitors are also emerging as potential treatments.

    • Conclusions:

    • The treatment of atopic dermatitis is evolving rapidly with the introduction of targeted biologic therapies and JAK inhibitors.
    • These novel therapies offer new hope for patients with severe or refractory AD.
    • The therapeutic options for AD are expanding significantly.